# Ranking Report — Cycle 2
## Session 006 (2026-03-21)

---

## Per-Hypothesis Scoring Tables

### H2.1: Pyocyanin-GPX4-Ferroptosis Bidirectional Axis

| Dimension | Score | Justification |
|---|---|---|
| Novelty | 7 | Full bidirectional cycle novel. Individual steps partially known. |
| Mechanistic Specificity | 9 | Every molecule named, kinetic timeline specified, 4 phases defined. |
| Testability | 9 | PYO + cells + ferrostatin-1 rescue. Simple, cheap, decisive. |
| Groundedness | 8 | Phases 1-3 fully grounded. Phase 4 parametric. |
| Impact | 8 | Ferrostatin-1 as adjunctive antibiotic. Selenium supplementation. |
| Counter-Evidence Resilience | 7 | FSP1 backup valid but not fatal. PYO-death specificity testable. |

**Composite Score: 8.15**
Calculation: 0.15(7) + 0.20(9) + 0.20(9) + 0.20(8) + 0.15(8) + 0.10(7) = 1.05 + 1.8 + 1.8 + 1.6 + 1.2 + 0.7 = 8.15

### H2.3: Dual-Pathway PYO + LoxA Synergy

| Dimension | Score | Justification |
|---|---|---|
| Novelty | 7 | LoxA known (Dar 2018). PYO-GSH known. Synergy novel. |
| Mechanistic Specificity | 8 | Two pathways specified. Synergy mechanism (GPX4 removal enables LoxA). |
| Testability | 9 | Mutant panel (WT vs phzM- vs PA1169- vs double). Unambiguous predictions. |
| Groundedness | 8 | Both pathways independently verified. Synergy prediction parametric. |
| Impact | 8 | Explains PA pathogenicity. Dual-target therapy prediction. |
| Counter-Evidence Resilience | 7 | Mutant data could refute. LoxA expression varies across strains. |

**Composite Score: 7.95**
Calculation: 0.15(7) + 0.20(8) + 0.20(9) + 0.20(8) + 0.15(8) + 0.10(7) = 1.05 + 1.6 + 1.8 + 1.6 + 1.2 + 0.7 = 7.95

### H2.2: GPX4 Gatekeeper with Scavenging Budget

| Dimension | Score | Justification |
|---|---|---|
| Novelty | 9 | Quantitative scavenging budget for inter-kingdom signaling is entirely new. |
| Mechanistic Specificity | 7 | Budget framework clear. Downstream bacterial effect unspecified. |
| Testability | 8 | 4-HNE flux measurement + QS reporter. Quantitative prediction. |
| Groundedness | 7 | GSH/albumin levels grounded. Budget calculation parametric. |
| Impact | 8 | Explains site-specific infection severity. GSH supplementation therapy. |
| Counter-Evidence Resilience | 6 | Effect on bacteria at achievable concentrations unknown. |

**Composite Score: 7.60**
Calculation: 0.15(9) + 0.20(7) + 0.20(8) + 0.20(7) + 0.15(8) + 0.10(6) = 1.35 + 1.4 + 1.6 + 1.4 + 1.2 + 0.6 = 7.55

### H2.6: ACSL4 Vulnerability Map

| Dimension | Score | Justification |
|---|---|---|
| Novelty | 7 | Novel framing of ACSL4 as ferroptosis-infection coupling predictor. |
| Mechanistic Specificity | 6 | Single-gene predictor is oversimplified. Needs ACSL4/GPX4 ratio. |
| Testability | 8 | Bioinformatic analysis free. Cell line comparison straightforward. |
| Groundedness | 6 | ACSL4 biology grounded. Cross-talk prediction speculative. |
| Impact | 6 | Incremental — provides framework, not breakthrough. |
| Counter-Evidence Resilience | 5 | Many confounders (GPX4, FSP1, iron levels, membrane composition). |

**Composite Score: 6.45**
Calculation: 0.15(7) + 0.20(6) + 0.20(8) + 0.20(6) + 0.15(6) + 0.10(5) = 1.05 + 1.2 + 1.6 + 1.2 + 0.9 + 0.5 = 6.45

### H2.5: Lactonase Degrades 4-HNE Lactol

| Dimension | Score | Justification |
|---|---|---|
| Novelty | 8 | Never proposed. |
| Mechanistic Specificity | 5 | Hemiacetal vs ester chemistry is uncertain. |
| Testability | 9 | One enzyme assay settles it. |
| Groundedness | 5 | Structural comparison imperfect. Substrate specificity uncertain. |
| Impact | 6 | If true, interesting but limited scope. |
| Counter-Evidence Resilience | 4 | Different bond type is significant concern. |

**Composite Score: 6.15**
Calculation: 0.15(8) + 0.20(5) + 0.20(9) + 0.20(5) + 0.15(6) + 0.10(4) = 1.2 + 1.0 + 1.8 + 1.0 + 0.9 + 0.4 = 6.30

---

## Final Ranking — Cycle 2

| Rank | ID | Title | Composite |
|---|---|---|---|
| 1 | H2.1 | Pyocyanin-GPX4-Ferroptosis Bidirectional Axis | 8.15 |
| 2 | H2.3 | Dual-Pathway PYO + LoxA Synergy | 7.95 |
| 3 | H2.2 | GPX4 Gatekeeper with Scavenging Budget | 7.55 |
| 4 | H2.6 | ACSL4 Vulnerability Map | 6.45 |
| 5 | H2.5 | Lactonase Degrades 4-HNE Lactol | 6.30 |

## Diversity Check
- H2.1: Bidirectional host-pathogen pathway (kinetics/systems)
- H2.3: Dual virulence mechanism synergy (microbial genetics)
- H2.2: Quantitative signaling framework (biochemistry/pharmacology)
- H2.6: Tissue-specific vulnerability prediction (genomics/systems biology)
- H2.5: Cross-kingdom enzyme substrate promiscuity (enzymology)
**All 5 conceptually distinct: PASS**

## Conditional Evolution Check
Top 3 all >= 7.5 composite. Diversity passed. No shared bridges.
**SKIP Evolver — proceed directly to Quality Gate.**
